These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 17027571)

  • 1. Relation of improvement in endothelium-dependent flow-mediated vasodilation after rosiglitazone to changes in asymmetric dimethylarginine, endothelin-1, and C-reactive protein in nondiabetic patients with the metabolic syndrome.
    Wang TD; Chen WJ; Cheng WC; Lin JW; Chen MF; Lee YT
    Am J Cardiol; 2006 Oct; 98(8):1057-62. PubMed ID: 17027571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome.
    Wang TD; Chen WJ; Lin JW; Chen MF; Lee YT
    Am J Cardiol; 2004 Feb; 93(3):362-5. PubMed ID: 14759393
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of rosiglitazone on endothelial function and inflammatory markers in patients with the metabolic syndrome.
    Esposito K; Ciotola M; Carleo D; Schisano B; Saccomanno F; Sasso FC; Cozzolino D; Assaloni R; Merante D; Ceriello A; Giugliano D
    Diabetes Care; 2006 May; 29(5):1071-6. PubMed ID: 16644639
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of rosiglitazone on endothelial function in men with coronary artery disease without diabetes mellitus.
    Sidhu JS; Cowan D; Kaski JC
    Am J Cardiol; 2004 Jul; 94(2):151-6. PubMed ID: 15246889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic effects of rosiglitazone in nondiabetic patients with metabolic syndrome.
    Aquilante CL; Kosmiski LA; Zineh I; Rome LC; Knutsen SD
    Pharmacotherapy; 2010 Mar; 30(3):236-47. PubMed ID: 20180607
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of rosiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome.
    Samaha FF; Szapary PO; Iqbal N; Williams MM; Bloedon LT; Kochar A; Wolfe ML; Rader DJ
    Arterioscler Thromb Vasc Biol; 2006 Mar; 26(3):624-30. PubMed ID: 16357312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of rosiglitazone alone and in combination with atorvastatin on nontraditional markers of cardiovascular disease in patients with type 2 diabetes mellitus.
    Chu CS; Lee KT; Lee MY; Su HM; Voon WC; Sheu SH; Lai WT
    Am J Cardiol; 2006 Mar; 97(5):646-50. PubMed ID: 16490430
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of combining simvastatin with rosiglitazone on inflammation, oxidant stress and ambulatory blood pressure in patients with the metabolic syndrome: the SIROCO study.
    Lazich I; Sarafidis P; de Guzman E; Patel A; Oliva R; Bakris G
    Diabetes Obes Metab; 2012 Feb; 14(2):181-6. PubMed ID: 21955403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia.
    Lu TM; Ding YA; Leu HB; Yin WH; Sheu WH; Chu KM
    Am J Cardiol; 2004 Jul; 94(2):157-61. PubMed ID: 15246890
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between protective effects of rosiglitazone on endothelium and endogenous nitric oxide synthase inhibitor in streptozotocin-induced diabetic rats and cultured endothelial cells.
    Wang S; Jiang JL; Hu CP; Zhang XJ; Yang DL; Li YJ
    Diabetes Metab Res Rev; 2007 Feb; 23(2):157-64. PubMed ID: 16770837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy.
    Kovacic JC; Martin A; Carey D; Wand H; Mallon PW; Feneley MP; Emery S; Cooper DA; Carr A;
    Antivir Ther; 2005; 10(1):135-43. PubMed ID: 15751771
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus.
    Kim HJ; Kang ES; Kim DJ; Kim SH; Ahn CW; Cha BS; Nam M; Chung CH; Lee KW; Nam CM; Lee HC
    Clin Endocrinol (Oxf); 2007 Feb; 66(2):282-9. PubMed ID: 17224000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peroxisome proliferator-activated receptor-gamma activation with pioglitazone improves endothelium-dependent dilation in nondiabetic patients with major cardiovascular risk factors.
    Campia U; Matuskey LA; Panza JA
    Circulation; 2006 Feb; 113(6):867-75. PubMed ID: 16461819
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The presence of metabolic syndrome is independently associated with elevated serum CD40 ligand and disease severity in patients with symptomatic coronary artery disease.
    Lee WL; Lee WJ; Chen YT; Liu TJ; Liang KW; Ting CT; Huey-Herng Sheu W
    Metabolism; 2006 Aug; 55(8):1029-34. PubMed ID: 16839837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammation, insulin, and endothelial function in overweight children and adolescents: the role of exercise.
    Kelly AS; Wetzsteon RJ; Kaiser DR; Steinberger J; Bank AJ; Dengel DR
    J Pediatr; 2004 Dec; 145(6):731-6. PubMed ID: 15580192
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rapid effects of rosiglitazone treatment on endothelial function and inflammatory biomarkers.
    Hetzel J; Balletshofer B; Rittig K; Walcher D; Kratzer W; Hombach V; Häring HU; Koenig W; Marx N
    Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1804-9. PubMed ID: 16002742
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of rosiglitazone treatment on plaque inflammation and collagen content in nondiabetic patients: data from a randomized placebo-controlled trial.
    Meisner F; Walcher D; Gizard F; Kapfer X; Huber R; Noak A; Sunder-Plassmann L; Bach H; Haug C; Bachem M; Stojakovic T; März W; Hombach V; Koenig W; Staels B; Marx N
    Arterioscler Thromb Vasc Biol; 2006 Apr; 26(4):845-50. PubMed ID: 16410460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin.
    Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
    Intern Med J; 2007 Feb; 37(2):79-86. PubMed ID: 17229249
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of peroxisome proliferator-activated receptor-gamma activation with pioglitazone on plasma adipokines in nondiabetic patients with either hypercholesterolemia or hypertension.
    Barac A; Campia U; Matuskey LA; Lu L; Panza JA
    Am J Cardiol; 2008 Apr; 101(7):980-5. PubMed ID: 18359318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus.
    Kelly AS; Thelen AM; Kaiser DR; Gonzalez-Campoy JM; Bank AJ
    Vasc Med; 2007 Nov; 12(4):311-8. PubMed ID: 18048467
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.